ReviewFrontiers in cell and developmental biology2019
CD90/Thy-1, a Cancer-Associated Cell Surface Signaling Molecule.
Review in Frontiers in cell and developmental biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 99 citations in OpenAlex.
- Intratumoral desmoplastic stroma in carcinoma brain metastases harbors stromal cells with a cancer-associated fibroblast (CAF)-like immunophenotype.Virchows Archiv : an international journal of pathology · 2026Article
- Integrated Transcriptomic Analysis and Machine Learning Identify THY1 as a Key Regulator of Cancer-Associated Fibroblast Infiltration, Promoting Malignant Progression and Immune Escape in Gastric Cancer.Journal of gastroenterology and hepatology · 2026Article
- Diving into the transcriptional landscape of leukemic stem cells in acute myeloid leukemia at single-cell resolution.Journal of cancer research and clinical oncology · 2026Review
- Balancing stromal-induced complexity in 3D ovarian cancer models through heterotypic co-culture with fibroblasts or architected micro-scaffolds.Journal of biological engineering · 2026Article
- Loss of CD90 alters EMT-associated features and drug sensitivity in U-CH1 chordoma cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Cancer stem cells: landscape, challenges and emerging therapeutic innovations.Signal transduction and targeted therapy · 2025Review
- Extended passaging of the SKOV3 ovarian cancer cell line leads to two phenotypically different strains.Disease models & mechanisms · 2025Article
- Identification and validation of hypoxia-associated genes positively correlated withTranslational cancer research · 2025Article
- Inhibiting the TGF-β1 Pathway Reduces the Aggressiveness of Intrahepatic CCA HuCCT1 CD90-Positive Cells.International journal of molecular sciences · 2025Article
- Isolation and characterization of canine umbilical cord mesenchymal/stromal stem cells.In vitro cellular & developmental biology. Animal · 2025Article
- Mesenchymal stromal/stem cells from perinatal sources: biological facts, molecular biomarkers, and therapeutic promises.Stem cell research & therapy · 2025Review
- The clinical potential of meniscal progenitor cells.The journal of cartilage & joint preservation · 2024Review
- Significance of CD70, VEGF, and CD90 Immunohistochemical Expression in Colorectal Cancer.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Cancer-associated fibroblasts: a versatile mediator in tumor progression, metastasis, and targeted therapy.Cancer metastasis reviews · 2024Review
- Unveiling heterogeneity in MSCs: exploring marker-based strategies for defining MSC subpopulations.Journal of translational medicine · 2024Review
- Low dose post-transplant cyclophosphamide and sirolimus induce mixed chimerism with CTLA4-Ig or lymphocyte depletion in an MHC-mismatched murine allotransplantation model.Bone marrow transplantation · 2024Article
- Characterization of CD90/Thy-1 as a crucial molecular signature for myogenic differentiation in human urine-derived cells through single-cell RNA sequencing.Scientific reports · 2024Article
- The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability.Cell reports · 2023Article
- Identifying dynamical persistent biomarker structures for rare events using modern integrative machine learning approach.Proteomics · 2023Article
- PerSEveML: A Web-Based Tool to Identify Persistent Biomarker Structure for Rare Events Using Integrative Machine Learning Approach.bioRxiv : the preprint server for biology · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD90 is a membrane GPI-anchored protein with one Ig V-type superfamily domain that was initially described in mouse T cells. Besides the specific expression pattern and functions of CD90 that were described in normal tissues, i.e., neurons, fibroblasts and T cells, increasing evidences are currently highlighting the possible involvement of CD90 in cancer. This review first provides a brief overview on CD90 gene, mRNA and protein features and then describes the established links between CD90 and cancer. Finally, we report newly uncovered functional connections between CD90 and endoplasmic reticulum (ER) stress signaling and discuss their potential impact on cancer development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.